BenzingaT3·5mo ago
TMED T. Rowe Price Health Care ETF
ETFETF quote, holdings, sector allocation, technicals, and options analytics. Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
TMED
—
—
Key stats
About
T. Rowe Price Health Care ETF (TMED) ETF
No description available.
- Exchange
- XNAS
- Inception
- 2025-06-11
- Has Options
- No
Fund profile
holdings as of Jun 30, 2026SEC filingthrough Jun 2026flows, SEC filings
- Expense ratio
- 0.44% prospectus, filed Feb 25, 2026
- Assets
- $23M SEC filing, Jun 30, 2026
- Trailing yield
- 0.48% paid annual
- Average daily volume
- $217K 30 sessions
- Holdings
- 102 top 10 are 47.5%
- Listed
- Jun 11, 2025 Nasdaq
Cost42
Liquidity11
Scale2
Diversification49
Moves with. US large-cap stocks (24% of its variance, beta 0.78); Small caps over large (9% of its variance, beta 0.38); Long Treasuries (5% of its variance, beta 0.30). These factors explain 41% of its daily moves over the last year.
Stated objective. The fund seeks long-term capital appreciation. (from the fund's prospectus)
All 102 holdingsFlow historySimilar fundsOverlap toolAll Health Care ETFs
Fund flows
through Jun 2026SEC filings- Jun 2026
- +$790K latest reported month
- Latest 3 months
- +$819K +3.5% of assets
- Latest 12 months
- +$9.0M +39.2% of assets
View as a table
| Month | Net flow |
|---|---|
| Jun 2026 | +$790K |
| May 2026 | −$29K |
| Apr 2026 | +$57K |
| Mar 2026 | +$1.4M |
| Feb 2026 | +$1.5M |
| Jan 2026 | +$1.5M |
| Dec 2025 | +$1.4M |
| Nov 2025 | −$1.4M |
| Oct 2025 | +$1.4M |
| Sep 2025 | $0 |
| Aug 2025 | +$1.2M |
| Jul 2025 | +$1.2M |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 15 months ago
Similar funds
| Fund | Overlap | Fee | Assets | 1Y | |
|---|---|---|---|---|---|
| TRUHVanEck Healthcare TruSector ETF | 49% | — | $833K | — | compare |
| XLVState Street Health Care Select Sector SPDR ETF | 48% | 0.08% | $43.5B | +18.2% | compare |
| VHTVanguard Health Care ETF | 47% | 0.09% | $19.3B | +18.4% | compare |
| FHLCFidelity MSCI Health Care Index ETF | 45% | 0.08% | $3.5B | +18.9% | compare |
| IYHiShares U.S. Healthcare ETF | 44% | 0.37% | $4.2B | +18.2% | compare |
Ranked by how much of the two portfolios is the same securities.
Look-through: what the holdings say
weights as of Jun 30, 2026SEC filing- Holdings vs fair value
- +5.7% 31% under, 29% over · 97% covered
- Price / earnings
- — 29% loss-making · 94% covered
- Price / book · sales
- 4.4 · 1.5 revenue growth +9.5%
- Above 200-day average
- 66% 56% above 50-day · by weight
- Short interest
- 5.7% of float, weighted · 4.2 days to cover
- Insider buying
- 13% of weight had net insider buying, 90 days; 70% net selling
- 13F holders
- +4.7% change in shares held by institutions, latest quarter
- Reporting earnings
- 6.6% of weight in 7 days; 17.3% in 14
Holdings reporting in the next 14 days · weighted implied move this week 0.47%
Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.
What changed in the portfolio
Mar 31, 2026 → Jun 30, 2026| Action | Holding | Weight before | Weight after | Shares vs flows |
|---|---|---|---|---|
| Exit | ABTABBOTT LABORATORIES | 3.91% | — | — |
| Exit | MDTMEDTRONIC PLC | 2.24% | — | — |
| Increase | ISRGINTUITIVE SURGICAL INC | 0.30% | 2.43% | +945.7% |
| Increase | PFEPFIZER INC | 0.00% | 1.91% | +857.4% |
| Increase | CORCENCORA INC | 1.06% | 2.75% | +225.0% |
| Increase | PODDINSULET CORP | 0.83% | 2.38% | +345.7% |
| Exit | BSXBOSTON SCIENTIFIC CORP | 1.47% | — | — |
| New position | MCKMCKESSON CORP | — | 1.46% | — |
| Exit | APLSAPELLIS PHARMACEUTICALS INC | 1.02% | — | — |
| Exit | REGNREGENERON PHARMACEUTICALS | 1.02% | — | — |
20 new, 28 exited, 22 increased and 33 decreased between the fund's two latest holdings reports; turnover 25.1%. Full holdings and history
Under the hood
fiscal year to Dec 31, 2025SEC census- Authorized participants
- 4 active of 19 with agreements; top 3 did 91%
- Created · redeemed
- $21M · $7.3M over the fiscal year
- Redemptions in kind
- 92% creations 78% in kind
- Creation unit
- 50,000 shares
- Securities lending
- 0.39% of assets on loan on average; earned 0.2 bp
From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.
ETF Profile
holdings as of 2026-12-31
Holdings
109
AUM
$20.3M
Provider
Nport
Inception
2025-06-11
Exchange
XNAS
Data As Of
2026-12-31
Expense Ratio
0.44%
Dividend Yield
0.48%
Distribution
Annual
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2025-12-23 | 2025-12-26 | $0.1616 | CD |
Asset Allocation
Top Holdings
top 50 of 109 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| LLY | ELI LILLY & CO | 14.48% | Equity (common) | US |
| UNH | UNITEDHEALTH GROUP INC | 6.54% | Equity (common) | US |
| TMO | THERMO FISHER SCIENTIFIC INC | 4.59% | Equity (common) | US |
| GILD | GILEAD SCIENCES INC | 4.14% | Equity (common) | US |
| ABT | ABBOTT LABORATORIES | 3.91% | Equity (common) | US |
| DHR | DANAHER CORP | 2.73% | Equity (common) | US |
| MDT | MEDTRONIC PLC | 2.24% | Equity (common) | IE |
| ALNY | ALNYLAM PHARMACEUTICALS INC | 2.06% | Equity (common) | US |
| SYK | STRYKER CORP | 2.00% | Equity (common) | US |
| DYN | DYNE THERAPEUTICS INC | 1.88% | Equity (common) | US |
| WAT | WATERS CORP | 1.75% | Equity (common) | US |
| BDX | BECTON DICKINSON AND CO | 1.71% | Equity (common) | US |
| A | AGILENT TECHNOLOGIES INC | 1.69% | Equity (common) | US |
| ELAN | ELANCO ANIMAL HEALTH INC | 1.59% | Equity (common) | US |
| HUM | HUMANA INC | 1.57% | Equity (common) | US |
| CYTK | CYTOKINETICS INC | 1.54% | Equity (common) | US |
| WST | WEST PHARMACEUTICAL SERVICES | 1.48% | Equity (common) | US |
| BSX | BOSTON SCIENTIFIC CORP | 1.47% | Equity (common) | US |
| ASND | ASCENDIS PHARMA A/S - ADR | 1.39% | Equity (common) | DK |
| BIIB | BIOGEN INC | 1.26% | Equity (common) | US |
| PCVX | VAXCYTE INC | 1.19% | Equity (common) | US |
| IMNM | IMMUNOME INC | 1.15% | Equity (common) | US |
| MTD | METTLER-TOLEDO INTERNATIONAL | 1.11% | Equity (common) | US |
| COR | CENCORA INC | 1.06% | Equity (common) | US |
| APLS | APELLIS PHARMACEUTICALS INC | 1.02% | Equity (common) | US |
| REGN | REGENERON PHARMACEUTICALS | 1.02% | Equity (common) | US |
| DXCM | DEXCOM INC | 1.01% | Equity (common) | US |
| CVS | CVS HEALTH CORP | 0.96% | Equity (common) | US |
| MLTX | MOONLAKE IMMUNOTHERAPEUTICS | 0.89% | Equity (common) | KY |
| PODD | INSULET CORP | 0.83% | Equity (common) | US |
| ADPT | ADAPTIVE BIOTECHNOLOGIES | 0.83% | Equity (common) | US |
| BCAX | BICARA THERAPEUTICS INC | 0.82% | Equity (common) | US |
| BNTX | BIONTECH SE-ADR | 0.80% | Equity (common) | DE |
| IMTX | IMMATICS NV | 0.80% | Equity (common) | NL |
| RGEN | REPLIGEN CORP | 0.79% | Equity (common) | US |
| COO | COOPER COS INC/THE | 0.78% | Equity (common) | US |
| STTK | SHATTUCK LABS INC | 0.77% | Equity (common) | US |
| IDXX | IDEXX LABORATORIES INC | 0.74% | Equity (common) | US |
| XENE | XENON PHARMACEUTICALS INC | 0.73% | Equity (common) | CA |
| SRPT | SAREPTA THERAPEUTICS INC | 0.73% | Equity (common) | US |
| BMY | BRISTOL-MYERS SQUIBB CO | 0.73% | Equity (common) | US |
| MOH | MOLINA HEALTHCARE INC | 0.71% | Equity (common) | US |
| APGE | APOGEE THERAPEUTICS INC | 0.69% | Equity (common) | US |
| CGON | CG ONCOLOGY INC | 0.68% | Equity (common) | US |
| AGIO | AGIOS PHARMACEUTICALS INC | 0.65% | Equity (common) | US |
| INCY | INCYTE CORP | 0.65% | Equity (common) | US |
| KYMR | KYMERA THERAPEUTICS INC | 0.62% | Equity (common) | US |
| NVO | NOVO-NORDISK A/S-SPONS ADR | 0.58% | Equity (common) | DK |
| CABA | CABALETTA BIO INC | 0.58% | Equity (common) | US |
| ALGN | ALIGN TECHNOLOGY INC | 0.54% | Equity (common) | US |
Geographic Breakdown
Chart
Seasonality
| Month | '25 | '26 | Avg |
|---|---|---|---|
| Jan | -- | -0.46% | -0.46% |
| Feb | -- | 2.23% | 2.23% |
| Mar | -- | -4.50% | -4.50% |
| Apr | -- | 2.54% | 2.54% |
| May | -- | 5.62% | 5.62% |
| Jun | -1.25% | 9.16% | 3.96% |
| Jul | -4.47% | -1.02% | -2.75% |
| Aug | 4.68% | 4.29% | 4.48% |
| Sep | 4.89% | -4.19% | 0.35% |
| Oct | 4.34% | 1.42%* | 2.88% |
| Nov | 6.80% | -- | 6.80% |
| Dec | -0.31% | -- | -0.31% |
| Total | 15.07% | 15.24% | 15.15% |
* Only 2 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $33.86
SMA 50: $34.70
SMA 200: $31.80
Current: $33.81
EMA 12: $33.65
EMA 26: $34.02
MACD: -0.3724 | Signal: -0.0175
BEARISH
ADX (14): 15.91
RANGE
+DI: 32.89
−DI: 33.78
Momentum Oscillators
RSI (14): 47.32
NEUTRAL
Stoch %K: 24.60
Stoch %D: 16.95
Williams %R: -52.81
Volume & Volatility
BB Upper: $34.70
BB Lower: $33.01
NEUTRAL
OBV: -59,917
Vol SMA 20: 5,237
Vol ROC: 277.12%
ATR: $0.53
True Range: $0.78
HV 20: 19.4%
HV 30: 18.6%
HV 60: 18.2%
Data Summary
Data Points: 334
Last Updated:
Date Range: 2025-06-12T00:00:00 – 2026-10-09T00:00:00
AI Analysis
LLM Stock Analysis Report: TMED
Executive Summary
BULLISH (Confidence Level: 7)
Key drivers:
- Bullish MACD signal indicating a trend reversal
- Neutral RSI reading, suggesting the stock is not overbought or oversold
- Low volatility, indicating a stable market environment
Primary risks:
- Potential for consolidation around the current price level
- Limited upside potential if the stock fails to break above recent highs
Investment thesis: TMED appears to be in the early stages of a new uptrend, supported by technical indicators and low volatility. However, the stock's price action will need to demonstrate sustainable momentum before considering it a strong buy opportunity.
Recent news sentiment impact: The neutral sentiment of the latest news headline has had little to no impact on the stock's price action.
Technical Analysis
Trend Direction: Medium-term (1-3 months) uptrend
Support/Resistance Levels:
- Resistance: $36.59 (Bollinger Band upper)
- Support: $34.86 (Bollinger Band lower)
Momentum Signals:
- RSI interpretation: Neutral (53.53)
- MACD signal: Bullish (0.30 / Signal: -0.09 / Histogram: 0.39)
- Bollinger Bands position: Neutral
Volume Analysis:
- Volume SMA 20: 8799.28
- On-Balance Volume (OBV): 1150.47
- Volume Rate of Change: 129.22%
News & Sentiment Analysis
Recent Headlines Summary: One neutral news headline with no significant market impact.
Sentiment Assessment: Neutral sentiment, indicating a lack of strong buying or selling pressure.
Catalyst Identification: No upcoming earnings or major events announced.
Market Narrative: The stock's price action is driven by technical indicators rather than recent news headlines.
Risk & Volatility Assessment
Beta Interpretation: Low risk (beta: 0.62)
Volatility Regime: Low volatility, indicating a stable market environment.
Options Market Signals:
- IV rank: N/A (positive = implied richer than realized)
- Put/call ratios: N/A
- Unusual activity: No significant activity detected
Downside Protection: Support levels and risk management considerations will focus on the $34.86 (Bollinger Band lower) level.
Market Context & Positioning
Sector Performance: TMED's performance is inline with its sector.
Institutional Activity: No notable institutional activity detected.
Correlation Analysis: The stock moves relatively in line with the market (R-squared: 0.43).
Relative Valuation: The stock trades at a reasonable valuation relative to its peers and industry averages.
Key Levels & Action Items
Critical Price Levels:
- Resistance: $36.59
- Support: $34.86
Breakout/Breakdown Levels:
- Break above $36.59 for further upside potential
- Break below $34.86 for potential downside risks
Time-Sensitive Catalysts: No upcoming earnings or major events announced.
Risk Management: Stop-loss levels and position sizing considerations will focus on the $34.86 (Bollinger Band lower) level, with a 2-3% stop-loss order in place.
Generated
News
All TMED news →
TMED Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 0.6060
Alpha: 10.28%
Correlation: 0.4285
R-Squared: 18.4%
Stock Volatility: 18.4%
Market Volatility: 13.0%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
TMED Institutional Ownership (13F)
Latest filings — 2026-06-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
Constituent Performance
Click any bar to view the full quote for that stock.
Constituents
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|